Kevin MacKenzie

Title: Kevin MacKenzie: Innovator in Rho Associated Kinase Inhibitors

Introduction

Kevin MacKenzie is a notable inventor based in Houston, Texas. He has made significant contributions to the field of medical research, particularly in the development of peptide inhibitors for Rho-associated kinase (ROCK). His work addresses critical health issues, including heart failure, which is a leading cause of morbidity and mortality in the United States.

Latest Patents

Kevin MacKenzie holds a patent for Rho associated kinase (ROCK) inhibitors and their use in treating various diseases. The patent describes peptide inhibitors that block ROCK1 activity in the presence of 1 mM ATP. The binding epitope on ROCK1 was mapped using chemical cross-linking to the Activation Loop, identifying a new class of inhibitory drugs. These peptides have the potential to treat several important diseases, including heart disease, pulmonary hypertension, arterial hypertension, glaucoma management, insulin resistance, kidney disease, hemolytic anemia, stroke, ischemia reperfusion injury, and acute myeloid leukemia. He has 1 patent to his name.

Career Highlights

Kevin MacKenzie is affiliated with the University of Houston System, where he continues to advance his research in the field of biomedicine. His innovative work has garnered attention for its potential impact on treating serious health conditions.

Collaborations

Some of his notable coworkers include Robert J Schwartz and Hua Zhang, who have contributed to his research endeavors.

Conclusion

Kevin MacKenzie is a pioneering inventor whose work on ROCK inhibitors holds promise for treating a range of serious diseases. His contributions to medical research are significant and continue to influence the field.